Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (LIBBY) Trial

Grants and Contracts Details

Description

Abstract This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC)/cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation in hospice care eligible patients with agitation and Alzheimer’s disease (AD) or other types of dementia (HAD) participants as measured by the Cohen-Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. Participants will be randomized 1:1 to receive either T2:C100, an oral combination of THC and CBD in a digestible oil, or placebo. Study drug (T2:C100 or placebo) will be administered as orally, or through a feeding tube, once in the morning and once in the evening. Doses may be given with or without food and may be mixed with anything for easier consumption.
StatusActive
Effective start/end date5/1/224/30/24

Funding

  • University of Southern California: $2.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.